Camizestrant extends PFS in advanced ER-positive breast cancer
Click Here to Manage Email Alerts
Camizestrant significantly extended PFS compared with fulvestrant among certain postmenopausal patients with advanced breast cancer, according to the agent’s manufacturer.
Camizestrant (AstraZeneca) is a next-generation oral selective estrogen receptor degrader (SERD).
The randomized phase 2 SERENA-2 trial assessed camizestrant at several dose levels compared with fulvestrant for patients with locally advanced or metastatic ER-positive, HER2-negative breast cancer who previously received endocrine therapy for advanced disease.
Researchers randomly assigned 240 patients to camizestrant or fulvestrant until disease progression.
Primary endpoints included PFS with camizestrant at two dose levels — 75 mg or 150 mg — vs. fulvestrant dosed at 500 mg. Secondary endpoints included safety, objective response rate and clinical benefit rate at 24 weeks.
The study met its primary endpoint, showing significantly improved PFS with camizestrant at the 75- and 150-mg dose levels.
“The results from SERENA-2 show that camizestrant provides a significant improvement in progression-free survival compared [with] fulvestrant, which has been used to treat patients with [hormone receptor]-positive breast cancer for almost 20 years,” lead investigator Mafalda Oliveira, MD, PhD, medical oncologist at Vall d’Hebron Institute of Oncology in Barcelona, Spain, said in an AstraZeneca-issued press release. “These results are meaningful, highlighting the potential of this next-generation oral SERD and supporting the ongoing research program.”
Complete data from SERENA-2 will be presented at a medical meeting.
Read more about
Click Here to Manage Email Alerts